Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Home
/
update
/
details

Tempest and Roche Partner to Advance Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

NextEdge Admin

10 Oct 2024

1 min 53 sec

Tempest Therapeutics, a clinical-stage biotech company focused on developing targeted and immune-mediated cancer therapies, announced an agreement with Roche to advance the combination of amezalpat (TPST-1120) with atezolizumab (Tecentriq®) and bevacizumab into a pivotal Phase 3 trial for first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC). Atezolizumab and bevacizumab are the current standard of care for this form of liver cancer, which has a high unmet need.

Under the agreement, Roche will supply atezolizumab globally, while Tempest will sponsor and lead the trial. This follows a successful Phase 1b/2 study where amezalpat combined with atezolizumab and bevacizumab showed a six-month improvement in median overall survival (OS) compared to the standard therapy. Tempest retains all rights to amezalpat.

“We're excited to advance amezalpat into a pivotal study, reinforcing our commitment with Roche to deliver groundbreaking cancer treatments,” said Stephen Brady, CEO of Tempest. Positive Phase 2 data showed the combination therapy’s potential to improve first-line HCC treatment, with enhanced survival benefits in key subpopulations. After meeting with the FDA, Tempest has aligned on the Phase 3 study plan, aiming to expedite the timeline with a pre-specified early efficacy analysis.